Irina Bonzheim
Deep learning-based scoring of tumour-infiltrating lymphocytes is prognostic in primary melanoma and predictive to PD-1 checkpoint inhibition in melanoma metastases.
Chatziioannou E, Roßner J, Aung T, Rimm D, Niessner H, Keim U, Serna-Higuita L, Bonzheim I, Kuhn Cuellar L, Westphal D, Steininger J, Meier F, Pop O, Forchhammer S, Flatz L, Eigentler T, Garbe C, Röcken M, Amaral T, Sinnberg T. Deep learning-based scoring of tumour-infiltrating lymphocytes is prognostic in primary melanoma and predictive to PD-1 checkpoint inhibition in melanoma metastases. EBioMedicine 2023; 93:104644.
07.06.2023Deep learning-based scoring of tumour-infiltrating lymphocytes is prognostic in primary melanoma and predictive to PD-1 checkpoint inhibition in melanoma metastases.
07.06.2023EBioMedicine 2023; 93:104644
Chatziioannou Eftychia, Roßner Jana, Aung Thazin New, Rimm David L, Niessner Heike, Keim Ulrike, Serna-Higuita Lina María, Bonzheim Irina, Kuhn Cuellar Luis, Westphal Dana, Steininger Julian, Meier Friedegund, Pop Oltin Tiberiu, Forchhammer Stephan, Flatz Lukas, Eigentler Thomas Kurt, Garbe Claus, Röcken Martin, Amaral Teresa, Sinnberg Tobias
Successful treatment of metastatic uveal melanoma with ipilimumab and nivolumab after severe progression under tebentafusp: a case report.
Reiter S, Schroeder C, Broche J, Sinnberg T, Bonzheim I, Süsskind D, Flatz L, Forschner A. Successful treatment of metastatic uveal melanoma with ipilimumab and nivolumab after severe progression under tebentafusp: a case report. Front Oncol 2023; 13:1167791.
03.05.2023Successful treatment of metastatic uveal melanoma with ipilimumab and nivolumab after severe progression under tebentafusp: a case report.
03.05.2023Front Oncol 2023; 13:1167791
Reiter Selina, Schroeder Christopher, Broche Julian, Sinnberg Tobias, Bonzheim Irina, Süsskind Daniela, Flatz Lukas, Forschner Andrea
TMB and BRAF mutation status are independent predictive factors in high-risk melanoma patients with adjuvant anti-PD-1 therapy.
Eckardt J, Schroeder C, Martus P, Armeanu-Ebinger S, Kelemen O, Gschwind A, Bonzheim I, Eigentler T, Amaral T, Ossowski S, Riess O, Flatz L, Garbe C, Forschner A. TMB and BRAF mutation status are independent predictive factors in high-risk melanoma patients with adjuvant anti-PD-1 therapy. J Cancer Res Clin Oncol 2022; 149:833-840.
22.02.2022TMB and BRAF mutation status are independent predictive factors in high-risk melanoma patients with adjuvant anti-PD-1 therapy.
22.02.2022J Cancer Res Clin Oncol 2022; 149:833-840
Eckardt Julia, Schroeder Christopher, Martus Peter, Armeanu-Ebinger Sorin, Kelemen Olga, Gschwind Axel, Bonzheim Irina, Eigentler Thomas Kurt, Amaral Teresa, Ossowski Stephan, Riess Olaf, Flatz Lukas, Garbe Claus, Forschner Andrea
Dasatinib overrides the differentiation blockage in a patient with mutant- D816V positive CBFβ-MYH11 leukemia
Kampa-Schittenhelm K, Vogel W, Bonzheim I, Fend F, Horger M, Kanz L, Soekler M, Schittenhelm M. Dasatinib overrides the differentiation blockage in a patient with mutant- D816V positive CBFβ-MYH11 leukemia. Oncotarget 2018; 9:11876-11882.
31.01.2018Dasatinib overrides the differentiation blockage in a patient with mutant- D816V positive CBFβ-MYH11 leukemia
31.01.2018Oncotarget 2018; 9:11876-11882
Kampa-Schittenhelm Kerstin, Vogel Wichard, Bonzheim Irina, Fend Falko, Horger Marius, Kanz Lothar, Soekler Martin, Schittenhelm Marcus